SBIR/STTR Research Award
TOPIC 382 - THE MICROSCOPIC IMAGING OF EPIGENETIC LANDSCAPE BREAST TUMOR DIFFERENTIATION (MIEL-BTD) ASSAY: A HIGH THROUGHPUT SCREEN TO IDENTIFY NOVEL THERAPEUTICS FOR BREAST CANCER.
Award amount
$299,923Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VALA SCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- CZZJVX2BKJF3
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Breast cancer is a deadly disease in modern society with limited therapeutics optionsTumor malignancy is likely due to tumor initiating cells that are relatively undifferentiatedThis project will develop an assay to identify chemical compounds that encourage differentiation of breast tumor cellsa strategy that has proven effective for other cancer typesThe Microscopic Imaging of Epigenetic Landscape Breast Tumor DifferentiationMIEL BTDassay will utilize Vala SciencesStructured Illumination MicroscopeICSIMto quantify changes in the patterns of histone tags within the nucleusassociated with the initiation of differentiation of breast epithelium towards milk productionPhase I of this Fast Track project will demonstrate feasibility utilizing MCFcellsrepresentative of ERlumenal breast tumorSKBRcellsHERneuand MDA MBtriple negativebreast tumor cellsin standardD cultures using a version of the MIEL BTD based upon immunolabelingPhase II will develop genetically encoded epigenetic probesGEEPsand tumor spheroidDculture modelsSIM and image analysis methods will be developed for increased resolution of sub nuclear patterns of epigenetic markersThe MIEL BTD assay will be utilized in contract research for discovery of novel breast cancer therapeuticsThe ICSIM will be marketed to both academic and pharmaceutical cancer researchers
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR PHASE 1 (NIH/NIMH TOPIC 002 - DEVELOPMENT OF NOVEL IN-VITRO AND IN-VIVO MODELS TO SUPPORT NEUROHIV RESEARCH)
- An assay suite featuring hiPSC-derived neurons and support cells, to test toxicants and industrial chemicals for developmental neurotoxic effects
- Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo & HIV ARTs)
- Neural Circuits, Kinetics and Energetics HTS of Human iPSC-Neurons, -Microglia, and -Astrocytes: AI-Enabled Platform for Target ID, and Drug Discovery and Toxicity (e.g., Cancer Chemo and HIV ARTs)
- Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
37 SBIR/STTR records share this UEI (2006–2024). Reported award amounts total $27,661,877. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services